ROSG - Rosetta Genomics Ltd. - Ordinar

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.4700
-0.0251 (-5.07%)
At close: 9:49AM EST
Stock chart is not supported by your current browser
Previous Close0.4951
Open0.5300
Bid0.48 x 20200
Ask0.53 x 200
Day's Range0.4700 - 0.5300
52 Week Range0.4700 - 0.5300
Volume39,500
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE7 months ago

    Rosetta Announces That Completion of Genoptix Transaction Uncertain

    OTC PINK: ROSGF)(the "Company") announced today that the pending of merger of a subsidiary of Genoptix, Inc. with the Company has not occurred as scheduled and that Genoptix has refused to provide assurances that it intends to complete the transaction. Unless the transaction is completed by May 30, 2018, the Company intends to file for bankruptcy protection in Israel and the United States. Genoptix has asserted the existence of a "Material Adverse Effect" affecting the Company and breaches of representations and warranties, which the Company disputes.

  • What Kind Of Risk Should You Expect For Rosetta Genomics Ltd (NASDAQ:ROSG)?
    Simply Wall St.7 months ago

    What Kind Of Risk Should You Expect For Rosetta Genomics Ltd (NASDAQ:ROSG)?

    If you are a shareholder in Rosetta Genomics Ltd’s (NASDAQ:ROSG), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRE7 months ago

    Nasdaq Hearing Panel Determined to Delist Shares of Rosetta Genomics from Nasdaq Stock Market Effective May 22, 2018

    PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 18, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) announced today that on May 18, 2018, it received a decision letter from NASDAQ Stock Market ("Nasdaq") following a hearing that was held on May 17, 2018, informing the Company that the Nasdaq Hearing Panel has determined to delist the shares of the Company from the Nasdaq Stock Market and will suspend trading in those shares effective at the open of business on Tuesday, May 22, 2018. On April 16, 2018, the Nasdaq staff notified the Company that it was in violation of Listing Rule 5250(f) for failure to timely pay its annual listing fee.

  • ACCESSWIRE7 months ago

    Rosetta Receives an Additional Delisting Notice from Nasdaq

    PHILADELPHIA, PAand REHOVOT, ISRAEL / ACCESSWIRE / May 7, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) announced today that on May 2, 2018, it received a "delinquency" delisting notice from NASDAQ Stock Market ("Nasdaq"). The Company has not yet filed its Form 20-F as required pursuant to Nasdaq's Listing Rule 5250(c)(2) for the period ended December 31, 2017.On May 1, 2018, the Company filed a Form 12b-25 stating that, "…the Company does not believe it will be able to file its Form 20-F within the fifteenth calendar day after its prescribed due date." Based upon this disclosure and the Company's failure to meet the terms of the Staff's extension concerning complying with Nasdaq's minimum stockholders' equity requirement pursuant to Nasdaq Listing Rule 5550(b) (the "Rule"), Nasdaq has determined that this serves as an additional basis for delisting the Company's securities from Nasdaq.

  • Has Rosetta Genomics Ltd (NASDAQ:ROSG) Improved Earnings Growth In Recent Times?
    Simply Wall St.7 months ago

    Has Rosetta Genomics Ltd (NASDAQ:ROSG) Improved Earnings Growth In Recent Times?

    Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Rosetta Genomics Ltd’s (NASDAQ:ROSG) track record on aRead More...

  • ACCESSWIRE8 months ago

    Rosetta Genomics Announces Shareholder Approval of Merger with Genoptix

    PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 26, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) today announced that its shareholders approved a proposed merger with a subsidiary of Genoptix, Inc. ("Genoptix") at an extraordinary general meeting of shareholders. At the closing, Rosetta will become a privately held company owned by Genoptix and its shares will cease to trade. Within five business days following the closing, the payment agent to be engaged for such purpose will provide instructions to each holder of record of Ordinary Shares of Rosetta which will explain how to surrender share certificates.

  • ACCESSWIRE8 months ago

    Shareholder Meeting Adjourned to April 26, 2018

    - Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix - If Shareholders Do Not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value PHILADELPHIA, ...

  • ACCESSWIRE8 months ago

    Rosetta Announces Resignation of CEO

    PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 10, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate ...

  • ACCESSWIRE8 months ago

    Action Required Before Potential Bankruptcy

    - If Shareholders Do Not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value - Price Per Ordinary Share Increased to an Estimated $0.42 - $0.50 - This is a New Shareholder ...

  • ACCESSWIRE8 months ago

    Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix

    - If Shareholders do not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value - This is a New Shareholder Meeting and all Shareholders of Record as of March 20, 2018 Need ...

  • ACCESSWIRE9 months ago

    Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide

    Genoptix Will Have Exclusive Distribution Rights in the U.S. and Non-exclusive Rights in Most Geographies Outside the U.S. CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 13, 2018 ...

  • ACCESSWIRE9 months ago

    Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix Merger

    Previously announced meeting date of April 6, 2018, for its extraordinary general meeting of shareholders, has been cancelled and rescheduled for April 17, 2018 New record date for shareholder meeting ...

  • ACCESSWIRE9 months ago

    Genoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics

    -First step in the process of Genoptix acquiring all of Rosetta Genomics -Next step is the completion of a merger for $8 million in cash pursuant to which value to Rosetta Genomics' equity holders is preliminarily ...

  • ACCESSWIRE10 months ago

    Genoptix Enters into New Agreements to Acquire Rosetta Genomics for $9 Million in Cash

    - Value to Rosetta Genomics' Equity Holders is Preliminarily Estimated to be $0.40 - $0.45 Per Ordinary Share, After Deductions for Debt, Warrant Termination Payments, Fees, Expenses and Other Items - ...

  • ACCESSWIRE10 months ago

    Rosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with Genoptix

    Although shares voted were more than 2-to-1 in favor of the merger, the proposal failed to secure a majority of shares outstanding Company considering alternative options with Genoptix LAKE FOREST, CA; ...

  • ACCESSWIRE10 months ago

    Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix

    Shares voted to date are running 3-to-1 in favor of the merger Emphasizes that shareholders as of December 27, 2017, regardless of whether or not they still hold their shares, are entitled to vote This ...

  • Dec. 22 Forum Update: "Merry Christmas" Edition
    GuruFocus.comlast year

    Dec. 22 Forum Update: "Merry Christmas" Edition

    A summary of value investing forum activity for December